InflaRx N.V. (IFRX) has decided to halt the development of Vilobelimab for the treatment of pyoderma gangrenosum following the results of an interim analysis from its phase III clinical trial.
The Independent Data Monitoring Committee (IDMC), which conducted an unblinded review of the trial data, recommended stopping the study due to a lack of efficacy.
Pyoderma gangrenosum is a rare condition that causes large, painful sores on the skin, particularly on the legs. There are no approved drugs for this disease in the U.S or Europe.
Vilobelimab was granted marketing authorization under exceptional circumstances by the European Commission for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome earlier this year. It is marketed under the brand name GOHIBIC in all 27 EU member states as well as Iceland, Liechtenstein, and Norway.
The company will now prioritize its resources on INF904, which is being explored for two immuno-dermatology indications, namely chronic spontaneous urticaria and hidradenitis suppurativa, in a single phase IIa basket study. Initial data from the phase IIa basket study is anticipated this summer.
IFRX has traded in a range of $0.82 to $2.81 in the last 1 year. The stock closed yesterday's trading at $1.82, down 1.62%.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.